Special Issue "Mesenchymal Stem/Stromal Cells in Immunity and Disease"
Deadline for manuscript submissions: 30 October 2019
Dr. Mehdi Najar
Laboratory of Clinical Cell Therapy, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Campus Erasme, Bâtiment de Transfusion (Level +1), Brussels 1070, Belgium
Website | E-Mail
Interests: mesenchymal stem/stromal cells (MSCs), tissue sources of MSCs, immunomodulation properties, extracellular vesicles (EVs), environmental challenges, efficient MSC immunotherapy
Due to their simple and easier isolation procedure as well as their great expansion potential, mesenchymal stem/stromal cells (MSCs) are increasingly considered as ideal candidates for different therapeutic applications. MSCs are multipotent fibroblast-like cells that can be virtually found in almost all tissues. The therapeutic effect of MSCs is mainly a result of their potent immunomodulatory functions. MSCs are not true immune cells but tissue precursor cells harboring a spectrum of therapeutically active molecules. Moreover, MSCs are environmentally responsive as they can actively sense their surroundings (inflammation, infection, and tissue damage) and modulate in consequence their fate and behavior. By nature, MSCs demonstrate plasticity in their immunomodulatory effects as a way of responding to these challenges. Accordingly, their use as immunotherapeutic strategies will present new hopes for treating patients with immunological and inflammatory diseases. A better understanding of the molecular mechanisms underlying the immunomodulatory effects of MSCs and, in particular, the influence of the local environment on their immuno-biology will improve the safety and efficiency of MSC-based therapy as well as help to achieve the appropriate therapeutic effect. Another strategy to enhance the therapeutic value of MSCs is to use their extracellular vesicles (EVs) as an alternative to cellular products. EVs can mediate the immunomodulatory effects of MSCs by transferring their cytokines, mRNA, or miRNA to the target cells. By selectively isolating these MSC-derived vesicles, they can be infused instead of the cells for different immunotherapy purposes.
In this Special Issue, we propose to present updates about the MSC immunomodulatory properties including their extracellular vesicles (EVs) and to discuss different opinions related to MSC source and type, and the effects of environmental signals on their immuno-biology. Your potential contribution based on your expertise in the field would certainly enrich this Special Issue.
Dr. Mehdi Najar
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Mesenchymal stem/stromal cells (MSCs) of different origins
- Immunological and inflammatory diseases
- MSCs and MSCs-free-based immunotherapeutic strategies
- Immunomodulatory mechanisms
- Local environment conditioning
- Improved MSC strategies